Wegovy HD is the brand name for the newly FDA-approved 7.2 mg dose of Wegovy (semaglutide)
The association of metformin with heart failure in patients with diabetes mellitus receiving anthracycline chemotherapy
To view a copy of this licence, visit About this article Cite this article Kim, TH., Shin, S
Key Highlights Orforglipron (Eli Lilly) * 13.6% weight loss in Phase 2 * 2.1% HbA1c reduction * Highest efficacy among the three molecules in Phase 2 * Subsequently confirmed efficacy in Phase 3 with up to 14.7% weight loss * First and only FDA-approved oral small-molecule GLP-1 receptor agonist (Foundayo) Elecoglipron (AstraZeneca) * 11.8% weight loss * 1.9% HbA1c reduction * Strong Phase 2b results * Currently advancing into a global Phase 3 program Aleniglipron (Structure Therapeutics) * 12.1% weight loss * 1.5% HbA1c reduction * Encouraging efficacy with ongoing Phase 3 development Phase 2 Efficacy Comparison Weight Loss * Orforglipron: 13.6% * Aleniglipron: 12.1% * Elecoglipron: 11.8% HbA1c Reduction * Orforglipron: 2.1% * Elecoglipron: 1.9% * Aleniglipron: 1.5% As Structure Therapeutics expanded their testing into the ACCESS II trial and evaluated higher doses (specifically escalation protocols reaching 180 mg and 240 mg), the efficacy numbers jumped significantly
1625 In contrast, structures of other class B1 GPCRs bound to calcitonin (CT), 26 calcitonin gene related peptide (CGRP), 27 maxadilan, 20 corticotropin-releasing factor (CRF) 22 or urocortin-1 (UCN1) 28 reveal a loop secondary structure near the agonist N-terminus, followed by either a short (CT-family peptides) or extended -helix
